Selvigaltin (GB1211), an orally accessible small molecule galectin-3 inhibitor developed for a therapy for liver fibrosis and cirrhosis, was evaluated to evaluate the influence of hepatic impairment on its pharmacokinetics and safety to handle regulatory prerequisites. Table 4 Statistical evaluation of dose proportionality on the pharmacokinetic parameters of GB1211 following https://kirkg554vgr8.blogoscience.com/profile